Opus Genetics (Nasdaq: IRD) announced that leadership will present program updates at multiple ophthalmology and gene‑therapy conferences in May 2026, including ARVO (May 3–7), ASGCT (May 11–15), Retina World Congress (May 14–17) and the Retinal Therapeutics Innovation Summit (May 1).
Presentations will cover preliminary Phase 1b/2a OPGx-BEST1 clinical data, preclinical OPGx-RHO work, and translational assays advancing their inherited retinal disease pipeline.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – IRD
-2.10%
-2.10%Session close to close
In the Apr 27 session, IRD declined 2.10%, reflecting a moderate negative market reaction.
This announcement outlines Opus Genetics’ participation in several May 2026 ophthalmology and gene t...
Analysis
This announcement outlines Opus Genetics’ participation in several May 2026 ophthalmology and gene therapy meetings, showcasing programs like OPGx-BEST1, OPGx-LCA5, and OPGx-RHO. It follows recent disclosures of extended funding into 2029 and earlier safety and efficacy signals. With an effective registration covering 7,374,632 resale shares and multiple advancing trials, key items to watch are subsequent detailed data updates, regulatory milestones such as the October 17, 2026 PDUFA date, and any changes in capital structure.
Key Figures
Financing facility size:$155 millionInitial tranche:$35 millionPro forma cash:$100 million+5 more
8 metrics
Financing facility size$155 millionStrategic Oberland Capital facility (up to amount available)
Initial tranche$35 millionFirst funding tranche under Oberland facility
Pro forma cash$100 millionEstimated cash after financing, extending runway into 2029
Year-end cash$45.1MCash balance at end of 2025
BCVA improvement12-letter gainEarly OPGx-BEST1 safety and efficacy signal
Outlined March 2026 investor conference participation and webcast availability.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent operational and recognition news has often produced modest and sometimes counterintuitive price reactions, with both positive and neutral headlines followed by small moves up or down.
Recent Company History
Over the last few months, Opus Genetics has reported financing, clinical, and visibility milestones. A March 2025 results update highlighted cash of $45.1M plus a ~$25.0M private placement to fund operations into H1 2028, alongside multiple advancing programs. An early April strategic facility offered up to $155 million in primarily non-dilutive capital, extending runway into 2029. The company also secured industry recognition and has regularly disclosed upcoming conference appearances, similar in nature to today’s ophthalmology meeting schedule.
Key Terms
phase 1b/2a, gene therapies, subretinal injection, tRNA, +1 more
5 terms
phase 1b/2amedical
"previously disclosed preliminary data from our ongoing Phase 1b/2a OPGx-BEST1 study"
Phase 1b/2a is a combined early-stage clinical study that first tests safety and optimal dosing in a small group and then expands to look for initial signs that the drug works in the target patients. Think of it as a prototype test followed by a small pilot run: it helps companies decide whether to invest in larger, more expensive trials. Investors watch these results because they reduce scientific uncertainty and can sharply affect a drug’s value and development timeline.
gene therapiesmedical
"a clinical-stage biopharmaceutical company developing gene therapies to restore vision"
Gene therapies are medical treatments that change or replace a person’s genetic instructions to fix or counteract a disease, using biological delivery methods to get the new material into cells — like repairing or swapping pages in a faulty instruction manual. They matter to investors because they can offer one-time or long-lasting cures with large market potential, but carry high development costs, regulatory scrutiny and manufacturing challenges that make outcomes binary and investment risky.
subretinal injectionmedical
"OPGx-RHO (scAAV2/5-RHO820-shRNA820) Delivered by Subretinal Injection in a Canine Model"
A subretinal injection is a medical procedure that places a drug, gene therapy, or cells directly into the thin space beneath the retina at the back of the eye, delivering treatment precisely where damaged vision cells live. For investors, it matters because this targeted approach can increase effectiveness but also raises surgical complexity, regulatory hurdles, costs and safety considerations that affect clinical success, commercialization timeline and market adoption—think of burying fertilizer under a lawn rather than sprinkling it on top.
tRNAmedical
"Therapeutic Platform for BEST-1-associated Blindness: Anticodon-Engineered tRNA and Gene Augmentation"
Transfer RNA (tRNA) is a small molecule in cells that carries building blocks called amino acids to the protein-making machinery, matching them to the instructions encoded in messenger RNA much like a delivery truck that reads an address on a package and drops off the right part. For investors, tRNA is important because it underlies how many biotech drugs, genetic tests, and manufacturing processes work; changes or innovations involving tRNA can affect a company’s research progress, regulatory approval prospects, and commercial potential.
scAAV2/5medical
"Nonclinical Efficacy and Toxicity Study of GMP-grade Vector OPGx-RHO (scAAV2/5-RHO820-shRNA820)"
scaav2/5 is an engineered gene‑therapy delivery vehicle built from a modified adeno‑associated virus that combines characteristics of two viral variants (2 and 5) and uses a self‑complementary genome to start producing the therapeutic gene faster. Think of it as a specialized mailing system that aims to deliver genetic instructions more quickly and efficiently to target cells. For investors, the vector choice affects how well a therapy works, how safe and scalable it is to manufacture, and therefore the clinical and commercial risk and upside.
RESEARCH TRIANGLE PARK, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Opus Genetics (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that members of its leadership team will participate in several leading ophthalmology and industry conferences.
“We look forward to sharing progress across our programs at ARVO and other leading meetings this May, including encouraging findings from our LCA5 and BEST1 gene therapy programs,” said Dr. George Magrath, Chief Executive Officer, Opus Genetics. “At ARVO, we will present previously disclosed preliminary data from our ongoing Phase 1b/2a OPGx-BEST1 study, alongside new preclinical and translational work advancing our pipeline. These meetings provide an important opportunity to engage with the ophthalmology community as we work to develop durable, one-time treatments for inherited retinal diseases.”
Therapeutic Platform for BEST-1-associated Blindness: Anticodon-Engineered tRNA and Gene Augmentation
Nonclinical Efficacy and Toxicity Study of GMP-grade Vector OPGx-RHO (scAAV2/5-RHO820-shRNA820) Delivered by Subretinal Injection in a Canine Model of RHO-adRP
Presentation Title: Retina Unplugged: Inherited and Rare Retinal Diseases
Date: May 14–17, 2026
Location: Fort Lauderdale, FL
About Opus Genetics Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. Opus Genetics is also advancing a small-molecule therapy, Phentolamine Ophthalmic Solution 0.75%, beyond its approved use for pharmacologically induced mydriasis, with a supplemental new drug application under review for presbyopia and an ongoing Phase 3 pivotal trial for mesopic, low contrast conditions after keratorefractive surgery (dim light disturbances). The Company is based in Research Triangle Park, NC. For more information, visit www.opusgtx.com.
Contacts:
Investors Jenny Kobin Remy Bernarda IR Advisory Solutions ir@opusgtx.com
What will Opus Genetics (IRD) present at ARVO May 3–7, 2026?
Opus Genetics will present preliminary Phase 1b/2a OPGx-BEST1 clinical data and new preclinical/translational work. According to the company, presentations include restoration of cone-mediated vision, adult preliminary OPGx-BEST1 results, and cell-based expression and potency assay development.
When and where is Opus Genetics presenting OPGx-RHO data in May 2026?
Opus Genetics will present OPGx-RHO nonclinical efficacy and toxicity data at ASGCT, May 11–15, 2026 in Boston. According to the company, the study uses GMP-grade OPGx-RHO delivered by subretinal injection in a canine RHO-adRP model.
What findings will Opus Genetics share about BEST1 programs at May 2026 meetings?
Opus Genetics will share preliminary OPGx-BEST1 clinical results and platform work at multiple May meetings. According to the company, content includes adult preliminary Phase 1b/2a data, gene augmentation approaches, and anticodon-engineered tRNA strategies for BEST1-associated blindness.
Which Opus Genetics presentation is scheduled for the Retinal Therapeutics Innovation Summit on May 1, 2026?
Opus Genetics will present on safety and efficacy of OPGx-RHO silence-and-replace gene therapy across two large animal models on May 1, 2026 in Denver. According to the company, the talk focuses on evidence supporting RHO-adRP therapeutic development.
How can investors follow Opus Genetics (IRD) updates from the May 2026 conferences?
Investors can follow conference presentations and industry coverage for timing and abstracts during May 2026. According to the company, leadership will present at ARVO, ASGCT, Retina World Congress, and the Retinal Therapeutics Innovation Summit with program-specific sessions noted above.
